CytoDyn (OTCMKTS:CYDY) Trading Down 2.5% - Should You Sell?

Key Points

• CytoDyn's share price declined by 2.5%, trading as low as $0.25, with a last trade at $0.26 and a significant drop in trading volume.
• The company reported an earnings per share (EPS) of (-$0.01) for the last quarter, indicating ongoing financial challenges.
• CytoDyn develops treatments for various conditions, including COVID-19 and HIV, and is focused on the clinical development of its drug leronlimab.

CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report)'s share price was down 2.5% on Monday . The stock traded as low as $0.25 and last traded at $0.26. Approximately 1,238,599 shares were traded during mid-day trading, a decline of 44% from the average daily volume of 2,208,560 shares. The stock had previously closed at $0.26.

CytoDyn Trading Down 2.5%

The firm has a 50 day moving average of $0.29 and a two-hundred day moving average of $0.29. The company has a market cap of $325.14 million, a PE ratio of 25.84 and a beta of 1.42.

CytoDyn (OTCMKTS:CYDY - Get Free Report) last issued its earnings results on Friday, July 25th. The biotechnology company reported ($0.01) EPS for the quarter.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.